• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Black Adults Are Still Underrepresented in Federally Funded Cardiovascular Trials

Black Adults Are Still Underrepresented in Federally Funded Cardiovascular Trials

September 13, 2021

NIH-funded cardiovascular trials still have a lot of work to do when it comes to increasing their enrollment of Black adults, a group that is disproportionately affected by cardiovascular disease but isn’t properly represented in clinical research, a new study has found.

Researchers at Duke, Harvard, Johns Hopkins, New York University and the University of Vermont conducted a systematic review of NIH-funded cardiovascular trials registered on ClinicalTrials.gov between 2000 and 2019, looking at their enrollment of Black adults and the recruitment strategies they employed. They found that Black patients were not proportionately enrolled in these trials despite the fact that they are at a greater risk of heart disease.

Of the 100 trials they assessed, nearly half (46 percent) of them had enrolled populations that were less than 25 percent Black, according to the study, which was published in the Journal of the American Heart Association. Additionally, almost a quarter of trials failed to specify what percentage of their trial population identified as Black.

And after analyzing the 62 trials with protocols that had been published, the researchers found that they seriously lacked diversity targets. Just 13 trials (21 percent) clearly mentioned recruitment goals for historically underrepresented populations and only a single trial reported that it had met its goal for recruiting Black participants.

On recruitment strategies, 56 trials (90 percent) said they had active recruitment strategies in place, including electronic medical record-based recruitment (47 percent), community-based recruitment (13 percent) and provider-based recruitment (58 percent). Just three of the 62 trial protocols explicitly mentioned bringing in community members to help design the trial, while only two trials had community members outside of academic medical institutions as co-authors.

“While there is a considerable need for research on effective strategies to improve enrollment of Black adults, the first step is for Black inclusion to be a priority at the trial design phase through defined recruitment targets and intentional recruitment strategies,” the researchers advised. “Greater transparency, tracking of recruitment yields by demographic group, involvement of local stakeholders in trial design, and support of recruitment research may also represent long?term strategies to address this tremendous disparity in cardiovascular disease research.”

Read the full study here: https://bit.ly/2YC8Eg1.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing